文献速递神经肌肉病脑血管病

HOPE-Duchenne试验:CAP-1002对DMD心脏和骨骼肌的影响

Cardiac and skeletal muscle effects in the randomized HOPE-Duchenne trial.
PubMed 文献 · Neurology · 2019-01-23

12个月时CAP-1002组MRI显示瘢痕面积显著减少、下壁收缩增厚改善,且低功能患者中8/9上肢功能改善而对照组无改善(p=0.007),安全性两组相似。

要点

  • 经冠状动脉输注CAP-1002在DMD患者中安全性良好,不良事件发生率与对照组相似
  • CAP-1002组12个月MRI显示瘢痕面积显著减少及下壁收缩增厚改善
  • 低功能CAP-1002组8/9患者上肢功能改善,对照组无改善(p=0.007)

核心结论

  • 经冠状动脉CAP-1002在DMD中看来安全,并在心脏和上肢功能方面显示长达12个月的疗效信号。
  • 因此值得对CAP-1002治疗DMD心肌和骨骼肌病开展未来临床研究。

研究设计与样本

  • HOPE-Duchenne为I/II期、随机、对照、开放标签试验(NCT02485938)。
  • 2016年1月至8月在美国3个医学中心入组,随访12个月,由独立数据与安全监察委员会提供安全监督。

主要发现

  • 治疗中出现的不良事件发生率两组相似。
  • 与基线相比,CAP-1002组12个月MRI显示瘢痕面积显著减少及下壁收缩增厚改善,对照组无此变化。
  • 低功能CAP-1002组9例中8例12个月时中远端PUL改善,对照组无改善(p=0.007)。

关键数值与推荐

  • 低功能CAP-1002患者中8/9上肢功能(中远端PUL)改善,对照组0例改善,p=0.007。
  • 证据等级:该I/II期研究提供Class II证据,表明经冠状动脉CAP-1002可行、看来安全且可能有效。

临床怎么用

  • 对于>12岁伴显著心肌纤维化的DMD患者,经冠状动脉CAP-1002可作为未来临床研究的方向。
  • 心脏MRI和上肢功能(PUL)可作为评估DMD心脏和骨骼肌疗效的指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the feasibility, safety, and efficacy of intracoronary allogeneic cardiosphere-derived cells (CAP-1002) in patients with Duchenne muscular dystrophy (DMD). METHODS: The Halt Cardiomyopathy Progression (HOPE)-Duchenne trial is a phase I/II, randomized, controlled, open-label trial (NCT02485938). Patients with DMD >12 years old, with substantial myocardial fibrosis, were randomized (1:1) to usual care (control) or global intracoronary infusion of CAP-1002 (75 million cells). Participants were enrolled at 3 US medical centers between January and August 2016 and followed for 12 months. An independent Data and Safety Monitoring Board provided safety oversight. Cardiac function and structure were assessed by MRI, and analyzed by a blinded core laboratory. Skeletal muscle function was assessed by performance of the upper limb (PUL). RESULTS: Twenty-five eligible patients (mean age 17.8 years; 68% wheelchair-dependent) were randomized to CAP-1002 (n = 13) or control (n = 12). Incidence of treatment-emergent adverse events was similar between groups. Compared to baseline, MRI at 12 months revealed significant scar size reduction and improvement in inferior wall systolic thickening in CAP-1002 but not control patients. Mid-distal PUL improved at 12 months in 8 of 9 lower functioning CAP-1002 patients, and no controls (p = 0.007). CONCLUSIONS: Intracoronary CAP-1002 in DMD appears safe and demonstrates signals of efficacy on both cardiac and upper limb function for up to 12 months. Thus, future clinical research on CAP-1002 treatment of DMD cardiac and skeletal myopathies is warranted. CLASSIFICATION OF EVIDENCE: This phase I/II study provides Class II evidence that for patients with DMD, intracoronary CAP-1002 is feasible and appears safe and potentially effective.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Taylor M, Jefferies J, Byrne B, et al. Cardiac and skeletal muscle effects in the randomized HOPE-Duchenne trial. Neurology. 2019. PMID: 30674601. doi:10.1212/WNL.0000000000006950

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。